Tikun Therapeutics

Tikun Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing cannabinoid-based therapies for patients with significant unmet medical needs. The company leverages over a decade of clinical data and proprietary genetics from its affiliate, Tikun Olam, to advance a pipeline of standardized cannabinoid medicines. Its lead candidate, Avidekel, is a high-CBD, low-THC formulation currently being evaluated in Phase 2 clinical trials for indications such as Crohn's disease, Autism Spectrum Disorder, and Epidermolysis Bullosa. By applying pharmaceutical-grade standards to cannabinoid research, Tikun Therapeutics aims to provide evidence-based treatments that are safe and effective. The company is headquartered in New York and operates with a focus on rigorous scientific validation.